Since approximately 90–95% of patients with acute myeloid leukaemia express the CD33 protein on the surface of their leukaemic myeloblasts, it is an example of an ideal tumour-specific target for antibody therapy [20]. This evidence concerns the gene CD33 and acute myeloid leukemia.